RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
-3.89%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$2.3B
AUM Growth
+$2.3B
(-5.7%)
Cap. Flow
+$111M
Cap. Flow
% of AUM
4.81%
Top 10 Holdings %
Top 10 Hldgs %
42.59%
Holding
80
New
11
Increased
12
Reduced
36
Closed
4
Top Buys
| 1 |
CTLT
CATALENT, INC.
CTLT
|
$40.1M |
| 2 |
DexCom
DXCM
|
$39M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$32.6M |
| 4 |
Sarepta Therapeutics
SRPT
|
$31.9M |
| 5 |
Bristol-Myers Squibb
BMY
|
$31.2M |
Top Sells
| 1 |
ONEM
1Life Healthcare, Inc. Common Stock
ONEM
|
$38.9M |
| 2 |
Xenon Pharmaceuticals
XENE
|
$37M |
| 3 |
Pliant Therapeutics
PLRX
|
$25.3M |
| 4 |
Akero Therapeutics
AKRO
|
$22.5M |
| 5 |
Amicus Therapeutics
FOLD
|
$21.1M |
Sector Composition
| 1 | Healthcare | 98.78% |
| 2 | Industrials | 1.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Amicus Therapeutics
FOLD
$2.34B
| $203M | 8.83% | 18,346,861 -1,902,928 | -9% | -$21.1M |
|
2
Krystal Biotech
KRYS
$4.27B
| $153M | 6.65% | 1,913,280 +16,635 | +0.9% | +$1.33M |
|
|
ISEE
3
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $102M | 4.44% | 4,205,206 -296,905 | -7% | -$7.22M |
|
|
DCPH
4
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $86.2M | 3.74% | 5,582,105 +1,988,788 | +55% | +$30.7M |
|
|
5
Akero Therapeutics
AKRO
$3.74B
| $78.2M | 3.39% | 2,044,389 -588,523 | -22% | -$22.5M |
|
|
6
Pliant Therapeutics
PLRX
$101M
| $77.8M | 3.38% | 2,925,648 -952,951 | -25% | -$25.3M |
|
7
Fate Therapeutics
FATE
$120M
| $73.9M | 3.2% | 12,957,222 | – | – |
|
8
Kymera Therapeutics
KYMR
$2.95B
| $71.4M | 3.1% | 2,410,769 -263,068 | -10% | -$7.79M |
|
9
Celldex Therapeutics
CLDX
$1.47B
| $67.6M | 2.93% | 1,879,739 -97,712 | -5% | -$3.52M |
|
10
Replimune Group
REPL
$422M
| $67.3M | 2.92% | 3,811,988 -1,019,721 | -21% | -$18M |
|
11
Zymeworks
ZYME
$1.12B
| $54.9M | 2.38% | 6,067,918 -108,000 | -2% | -$976K |
|
12
Penumbra
PEN
$10.6B
| $52.4M | 2.27% | 187,992 -33,817 | -15% | -$9.42M |
|
13
LivaNova
LIVN
$3.08B
| $51.7M | 2.24% | 1,186,418 +80,009 | +7% | +$3.49M |
|
14
Beam Therapeutics
BEAM
$1.66B
| $49.4M | 2.14% | 1,612,094 -158,493 | -9% | -$4.85M |
|
15
Jazz Pharmaceuticals
JAZZ
$7.75B
| $49M | 2.13% | 335,159 +16,214 | +5% | +$2.37M |
|
16
argenx
ARGX
$43.6B
| $48.6M | 2.11% | 130,540 -17,977 | -12% | -$6.7M |
|
|
17
Xenon Pharmaceuticals
XENE
$2.98B
| $47.5M | 2.06% | 1,325,832 -1,034,582 | -44% | -$37M |
|
|
IGMS
18
DELISTED
IGM Biosciences
IGMS
| $45.8M | 1.99% | 3,334,355 | – | – |
|
|
OSH
19
DELISTED
Oak Street Health, Inc.
OSH
| $41.1M | 1.78% | 1,061,295 -359,322 | -25% | -$13.9M |
|
|
CTLT
20
DELISTED
CATALENT, INC.
CTLT
| $40.1M | 1.74% | +610,304 | New | +$40.1M |
|
|
21
DexCom
DXCM
$29.5B
| $39M | 1.69% | +336,048 | New | +$39M |
|
22
Stryker
SYK
$150B
| $39M | 1.69% | 136,464 +30,584 | +29% | +$8.73M |
|
23
Stoke Therapeutics
STOK
$1.08B
| $34.5M | 1.5% | 4,145,396 +3,502,966 | +545% | +$29.2M |
|
|
24
BioMarin Pharmaceuticals
BMRN
$11.2B
| $32.6M | 1.41% | +335,170 | New | +$32.6M |
|
|
25
Sarepta Therapeutics
SRPT
$1.78B
| $31.9M | 1.39% | +231,595 | New | +$31.9M |
|